Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company’s research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company’s web site at www.genta.com.
- 17 years ago
QualityStocks
Generex Biotechnology Corporation (NASDAQ: GNBT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Reports Q3 2025 Net Income of $1.5 Million and 42% Gross Margin, Highlighting Strong Operational Turnaround
Massimo Group (NASDAQ: MAMO), a provider of powersports vehicles and related equipment, reported revenue of…
-
QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Completes Montauban Mill Building, Moves Toward Commissioning and First Gold-Silver Production in 2026
This article has been disseminated on behalf of ESGold Corp. and may include paid advertising. ESGold…
-
QualityStocksNewsBreaks – D-Wave (NYSE: QBTS) Advantage2TM Quantum Computer Now Available for U.S. Government Applications at Davidson Technologies
D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a global leader in quantum computing systems, software and…